EU/3/10/751: Orphan designation for the prevention of delayed graft function after renal transplantation

Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)

Table of contents

Overview

On 6 June 2010, orphan designation (EU/3/10/751) was granted by the European Commission to Verius Limited, United Kingdom, for synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for the prevention of delayed graft function after renal transplantation.

This medicine is now known as teprasiran.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in August 2019.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

Key facts

Active substance
Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)
Intended use
Prevention of delayed graft function after renal transplantation
Orphan designation status
Withdrawn
EU designation number
EU/3/10/751
Date of designation
06/06/2010
Sponsor

Clinical Network Services (NL) B.V.
De Cuserstraat 93
Amsterdam
Noord-Holland
1081 CN
The Netherlands 
E-mail: hannah.lewis@clinical.net.au

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating